Odyssey Therapeutics Appoints Timothy P. Walbert and Ian F. Smith to Board of Directors
Slice of Healthcare Team
Oct 08, 2024
Key Highlights
- Timothy P. Walbert: Former Chairman, President & CEO of Horizon Therapeutics, instrumental in $28.3 billion acquisition by Amgen.
- Ian F. Smith: Former Executive Vice President and COO of Vertex Pharmaceuticals, pivotal in transforming Vertex into a global biotech leader.
- Both Directors bring a combined 60+ years of leadership in the biopharma industry.
- Appointment strengthens Odyssey’s position in advancing next-generation immunomodulators for inflammatory diseases.
Source: Business Wire
Notable Quotes
“ Tim’s legacy in the industry is hallmarked by the acquisition, development and commercialization of numerous life-changing therapies at Horizon that led to one of the largest biopharma acquisitions in recent years. ”
Jeff Leiden, M.D., Ph.D., Chairman at the Odyssey Board
“ As we advance our lead programs into and through the clinic... we look forward to leveraging the insights of Ian, Tim, and the rest of our accomplished Board. ”
Gary D. Glick, Ph.D., CEO at Odyssey Therapeutics
